UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

7 Nov 2023

UCB launches an offer to the public of 6-year 5.20% fixed rate notes in Belgium and in Luxembourg

Read More
1 Nov 2023

UCB presents latest data from generalized myasthenia gravis portfolio at 2023 AANEM Annual Meeting and MGFA Scientific Session

Read More
18 Oct 2023

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

Read More
17 Oct 2023

UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis

Read More
13 Oct 2023

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Read More
12 Oct 2023

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Read More

Stay up-to-date on the latest news and information from UCB